|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.34 HKD | +2.90% |
|
-9.35% | -12.84% |
| 03-04 | Abbisko Doses First Patient in Tumor Drug Trial | MT |
| 03-03 | Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share | RE |
| Capitalization | 6.54B 7.41B 948M 815M 740M 709M 1.3B 87.37B 1.34B 8.69B 3.48B 41.67B 3.56B 3.48B 149B | P/E ratio 2025 |
130x | P/E ratio 2026 * | -274x |
|---|---|---|---|---|---|
| Enterprise value | 4.68B 5.3B 678M 583M 529M 507M 927M 62.5B 960M 6.22B 2.49B 29.81B 2.55B 2.49B 106B | EV / Sales 2025 |
12.8x | EV / Sales 2026 * | 22.3x |
| Free-Float |
79.42% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | +2.90% | ||
| 1 week | -9.35% | ||
| Current month | -10.78% | ||
| 1 month | -11.75% | ||
| 3 months | -20.14% | ||
| 6 months | -37.73% | ||
| Current year | -12.84% |
| 1 week | 10.77 |  | 12.8 |
| 1 month | 10.77 | | 13.58 |
| Current year | 10.77 | | 14.99 |
| 1 year | 5.52 | | 19.78 |
| 3 years | 2.05 | | 19.78 |
| 5 years | 2.05 | | 19.78 |
| 10 years | 2.05 | | 19.78 |
| Manager | Title | Age | Since |
|---|---|---|---|
Hong Ping Yu
CTO | Chief Tech/Sci/R&D Officer | 58 | 28/02/2022 |
Yao Chang Xu
CEO | Chief Executive Officer | 69 | 27/03/2018 |
Zi Dong Zhang
DFI | Director of Finance/CFO | 45 | 15/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Yao Chang Xu
CHM | Chairman | 69 | 27/03/2018 |
Hong Ping Yu
BRD | Director/Board Member | 58 | 27/03/2018 |
Piao Yang Sun
BRD | Director/Board Member | 67 | 29/09/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.90% | -9.35% | +47.27% | +275.50% | 948M | |
| +0.19% | -1.23% | +8.75% | +100.25% | 45.72B | |
| -1.85% | -7.84% | +52.40% | +10.53% | 39.82B | |
| +1.96% | +0.85% | +94.12% | +627.57% | 32.31B | |
| +3.02% | -5.50% | -5.34% | -20.62% | 26.05B | |
| +0.40% | -7.42% | +53.42% | -38.10% | 18.68B | |
| -0.46% | -2.26% | +8.37% | -29.82% | 17.17B | |
| +7.03% | +0.10% | +38.87% | +134.75% | 11.23B | |
| +1.79% | -1.91% | -19.43% | +898.70% | 11.93B | |
| +2.33% | -6.84% | +8.88% | +143.09% | 10.83B | |
| Average | +1.73% | -7.09% | +28.73% | +210.19% | 21.47B | |
| Weighted average by Cap. | +0.96% | -6.17% | +32.03% | +174.95% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 637M 721M 92.23M 79.31M 71.97M 69.02M 126M 8.5B 131M 845M 339M 4.05B 346M 339M 14.48B | 235M 266M 34.05M 29.28M 26.57M 25.48M 46.53M 3.14B 48.21M 312M 125M 1.5B 128M 125M 5.35B |
| Net income | 77.07M 87.29M 11.17M 9.6M 8.71M 8.36M 15.26M 1.03B 15.81M 102M 40.98M 491M 41.91M 41.01M 1.75B | -4.57M -5.18M -662K -569K -517K -496K -905K -61.04M -938K -6.07M -2.43M -29.11M -2.49M -2.43M -104M |
| Net Debt | -1.86B -2.11B -270M -232M -210M -202M -369M -24.87B -382M -2.47B -990M -11.86B -1.01B -991M -42.35B | -1.3B -1.48B -189M -163M -148M -141M -258M -17.43B -268M -1.73B -694M -8.31B -710M -694M -29.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/03/26 | 11.34 $ | +2.90% | 2,166,000 |
| 04/03/26 | 11.02 $ | -1.17% | 1,744,279 |
| 03/03/26 | 11.15 $ | -6.14% | 4,112,000 |
| 02/03/26 | 11.88 $ | -6.53% | 1,303,000 |
| 27/02/26 | 12.71 $ | +1.60% | 2,287,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2256 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition